
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
SEQSTER and PatientsLikeMe (PLM) have collaborated to launch a rare-disease study focused on Alpha-1 Antitrypsin Deficiency (AATD). The study aims to better understand how to reduce delays in diagnosis, decrease disparities in care, and improve outcomes in patients with AATD.
Read more about the study






